asparlas
(calaspargase pegol)Servier Pharmaceuticals LLC
Usage: ASPARLAS is indicated for use as part of a multi-agent chemotherapy regimen to treat acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years.
15 results
cyclophosphamide
(Cyclophosphamide)NorthStar RxLLCUsage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric patients with minimal change nephrotic syndrome who do not respond to corticosteroids.cyclophosphamide
(cyclophosphamide)Baxter Healthcare CorporationUsage: Cyclophosphamide for Injection is indicated for treating various malignancies in adults and pediatric patients, including malignant lymphomas, multiple myeloma, leukemias, and specific cancers like breast and ovarian carcinoma. It's also used for pediatric minimal change nephrotic syndrome when corticosteroid therapy fails.cyclophosphamide
(Cyclophosphamide)Amneal Pharmaceuticals LLCUsage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, several types of leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids.cyclophosphamide
(cyclophosphamide)Bamboo US Bidco LCCUsage: Cyclophosphamide is indicated for treating various malignant diseases, including lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids. Safety in adults for this condition is not established.imatinib mesylate
(IMATINIB MESYLATE)Camber Pharmaceuticals, Inc.Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), blast crisis, and acute lymphoblastic leukemia (ALL) in adults and pediatrics, as well as for myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.imatinib mesylate
(Imatinib Mesylate)Chartwell RX, LLCUsage: This drug is indicated for treatment of Philadelphia positive chronic myeloid leukemia (CML) in various phases, acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).imatinib mesylate
(Imatinib Mesylate)Apotex CorpUsage: This drug is indicated for the treatment of newly diagnosed and resistant Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), various myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastro-intestinal stromal tumors (GIST).jylamvo
(Methotrexate)SHORLA ONCOLOGY INC.Usage: JYLAMVO is indicated for treating acute lymphoblastic leukemia in adults and pediatric patients, mycosis fungoides, relapsed non-Hodgkin lymphomas, rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in pediatrics, and severe psoriasis in adults.leukine
(SARGRAMOSTIM)Partner Therapeutics, Inc.Usage: LEUKINE is indicated for shortening neutrophil recovery and reducing severe infections in adults with acute myeloid leukemia post-chemotherapy, mobilizing progenitor cells for transplantation, accelerating recovery in bone marrow transplants, treating delayed neutrophil recovery, and increasing survival after acute exposure to myelosuppressive radiation in patients up to 17 years.